News
Company News: Curetis to Report its Half-Year Results 2018 on August 14, 2018
– Company will host earnings conference call and webcast
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it will publish its financial results for the first six months ended on June 30, 2018, on August 14, 2018. In addition, the Company will host a public conference call and webcast on August 14, 2018, at 12:30 pm CEST / 06:30 am EDT to present the H1-2018 financial results, highlight the most important events and provide an outlook for the second half of 2018 and beyond.
Company News: Curetis Subsidiary Ares Genetics Launches ARES & CO Pharma Partnering Program
— Program aims to counteract antibiotic resistance by use of artificial intelligence in drug development
Curetis N.V. (the “Company” and together with its subsidiaries “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the launch of the ARES & CO (Antibiotic RESistance Solutions by COoperative R&D) pharma partnering program by its wholly-owned subsidiary Ares Genetics GmbH based in Vienna, Austria. The program aims at establishing an alliance for antibiotic stewardship with pharmaceutical companies and contract research organizations. The program is supported and largely funded by the Vienna Business Agency.
Company News: Curetis Reports Results of the Annual General Meeting Held on June 21, 2018
– All proposed AGM resolutions approved by shareholders
Curetis N.V. (the “Company” and together with its subsidiaries “Curetis“), a developer of next-level molecular diagnostic solutions, today reported the results of its Annual General Meeting (“AGM”) held in Amsterdam on June 21, 2018.
Company News: Project Group ProDetekt at Life Science Inkubator (LSI) Sachsen extends patent protection for PRET-ELISA technology to the U.S.
– Solution enables significant optimization of ELISA-based protein analytics
Dresden, Germany, June 21, 2018 – ProDetekt, a start-up project incubated at Life Science Inkubator Sachsen, has been granted a U.S. patent for its proprietary PRET-ELISA technology, which complements the ELISA method used in bioanalytics world-wide. The Company had already received broad European patent protection for its technology in March 2018.